Adherence to statin treatment following a myocardial infarction: an Italian population-based survey

Abstract

Background

Statins are standard therapies after myocardial infarction (MI) in the general population. In the current study, we assessed adherence to statin treatment by patients after an MI in Italy, and estimated the effect of in-hospital statin therapy on persistence in treatment during a 2-year follow-up.

Patients and methods

This was a retrospective cohort observation study of patients who experienced their MI between January 1, 2004 and December 31, 2005. Patients to enroll were identified by a diagnosis of MI at discharge from hospital. Previous drug therapies and hospital admissions for cardiovascular reasons in the 12 months before hospitalization for MI, statin treatment and lipid levels during hospitalization, indication for statin treatment at hospital discharge, and adherence to statin treatment in the following 24 months using an integrated analysis of administrative databases and hospital case records were evaluated. Also, factors associated either positively or negatively with consistent acute and long-term use of this efficacy-proven therapy were evaluated.

Results

We identified 3,369 patients: 28.5% of patients had not been consistently treated with statins during their hospital stay for MI, and 36.2% of patients did not receive a statin prescription at hospital discharge. Of the 2,629 patients persistent with treatment during the follow-up, only 1,431 had an adherence to statins >80%. Either during the hospitalization or during the follow-up, the use of statins was negatively associated with older age and the presence of diabetes and chronic kidney disease. Lipid levels were significantly higher in treated than in untreated patients, but did not contribute to adherence to treatment. An important factor in long-term adherence to statin treatment was a statin prescription at the time of hospital discharge.

Conclusion

Since the statin undertreatment rate in routine care is still high, physicians need to increase the awareness of patients regarding the implications of discontinuation and/or underuse of their medications and encourage higher adherence.

Keywords:

• myocardial infarction
• statins
• adherence to treatment
• discontinuation

Introduction

There is general agreement that all coronary artery disease (CAD) patients should be treated with statins irrespective of their serum cholesterol level.^1–4 Moreover, in patients with acute coronary syndrome, early statin therapy using high-dose atorvastatin significantly lowered recurrent ischemic events.⁵ Despite the well-established benefits and abundance of clinical management guidelines advocating statin use in high-risk cardiac conditions,^6–8 the direct translation of trial results to individual patients in clinical practice is however still unsatisfactory. The therapeutic effect of a drug depends not only on patients having the treatment prescribed but also on their adherence with the treatment. Data from the US show that only half to three-quarters of patients who have had a myocardial infarction (MI) are even being screened for serum cholesterol levels, much less being prescribed lipid-lowering regimens.⁹ Moreover, previous studies have shown that long-term adherence to statin regimens in patients who are appropriate candidates has generally been poor, and continued use of statins drops substantially over time.^10,11 In this context, the environment in which healing and disease prevention take place, including the behavior of physician and that of patients, play a leading role. Programs aimed at fostering systems-based hospital care of CAD patients from admission to discharge incorporating evidence-based tools into practice and targeting patients resulted in a significant lowering of short- and long-term mortality.¹² This is important, since it is known that prescription for statins at the time of hospital discharge enhances long-term statin adherence.¹³

The present study aimed to investigate adherence to statin treatment by patients after an MI in Italy, and to estimate the effect of in-hospital statin therapy on persistence in treatment during a 2-year follow-up.

Patients and methods

Data source

In a nonconcurrent cohort study design, data were abstracted from administrative databases maintained by nine local health units (LHUs) in Italian regions in the north (Lombardy, Veneto, Emilia-Romagna), the center (Tuscany, Abruzzo, Lazio), and the south (Apulia). Overall, the served populations include approximately 4,000,000 inhabitants. Each LHU ethics committee approved the study. The databases used were beneficiaries, pharmacy claims, hospital discharges, and mortalities, and were all linked using the fiscal code as a unique identifier. Beneficiary and pharmacy claim databases are updated monthly, the hospital discharge database every 2 or 3 months, and the mortality database annually. Universal health care coverage in Italy allows completeness and comprehensiveness of the information contained in these databases, which in a previous epidemiological study showed almost complete (>95%) linkage.¹⁴ The Italian Ministry of Health has reported that archives are 100% complete and 95% accurate.¹⁵ In order to guarantee patient privacy, each subject was assigned an anonymous univocal alphanumeric code.

Cohort definition

Records of patients aged 18 years or over discharged from hospital between January 1, 2004 and December 31, 2005 with a main diagnosis of MI (International Classification of Diseases [ICD]-9 code 410), were selected from the hospital discharge database, which contains the dates of hospital admission and discharge and the discharge diagnoses. We excluded subjects who died, as well as those who moved to other LHUs in a 24-month follow-up, starting from the date of hospital discharge (index date). The same database provided information also on occurrence of hospital admissions in the 12 months preceding the index date for the following reasons: coronary heart disease (ICD-9 410–414), heart failure (ICD-9 428), cerebrovascular disease (ICD-9 430–438), peripheral vascular disease (ICD-9 440–443), and diabetes (ICD-9 250). From the beneficiary database, demographics, place of residence, and date of entry in and exit from the database were obtained. The pharmacy claim database is generated from requests to the LHUs for reimbursement of prescription drugs dispensed by pharmacies to outpatients in the community and covered by the Italian National Health Service. It was used to retrieve the prescribing physician’s code, the anatomical–therapeutic–chemical (ATC) code, the number of packs, the number of units per pack, the dosage (strength per unit drug), the cost per pack, and the prescription date of each drug dispensed. The defined daily dose of statin has been established by the World Health Organization:¹⁶ 20 mg for atorvastatin, 30 mg for pravastatin, 10 mg for rosuvastatin, and 30 mg for simvastatin. The presence of at least two prescriptions for hypoglycemic drugs (ATC code A10), antiplatelet drugs (ATC code B01), and antihypertensive drugs (ATC codes C02, C03, C07, C08, and C09) was considered to represent a treatment for diabetes, prevention of thrombosis, and hypertension, respectively, either in the 12-month period prior or in the 24-month period following the index date. In-hospital case history had been looked up to check determination of total and low-density-lipid (LDL) cholesterol levels (in cases of two or more values, we had considered the first determination), in-hospital statin treatment, and statin prescription at discharge from the hospital. The mortality database was used to obtain vital status and date of death in the follow-up.

Adherence to statin treatment

The adherence to statin treatment was determined in the 24-month follow-up period. Patients who received only one prescription for statin were defined as “occasionals”. In persistent patients (those who received two or more prescriptions), adherence was determined using the medication-possession ratio (MPR). The MPR reflects the proportion of days during which the patients possessed a supply medication: $\text{MPR}=\frac{\text{Sum of day’s supply during follow-up period}}{\text{Total number of days of follow-upperiod}(730)}$(1)

For patients treated with two or more statins, the MPR reported was calculated as the mean of the MPR calculated for each drug. We excluded from the MPR calculation the number of days eventually spent by the patient in an institutionalized care setting, such as a hospital. Patients were defined as adherent to statin treatment if their MPR was equal or over 80%.¹⁷ The mean daily dose of statin, expressed in mg/day, was calculated as the total amount of statin/the number of days of follow-up.

Statistical analysis

Data are summarized as means ± standard deviation for continuous variables and as percentages for categorical variables. Differences in categorical variables were tested using Pearson’s χ² test, considering results for trend when appropriate.

Logistic regression, with relative risk and 95% confidence interval, was used to predict 2-year nonadherence to statin treatment. Covariates included in the models were demographics (age and sex), statin treatment before hospital admission, diabetes, previous cardiovascular (CV) hospitalizations, chronic kidney disease (CKD), statin treatment during hospitalization, concomitant antihypertensive and antithrombotic treatments, and statin prescribed during the follow-up. Analyses were performed using the SPSS statistical package, version 20.0 for Windows (IBM, Armonk, NY, USA). A P-value <0.05 was considered statistically significant.

Results

Over the 2-year period, 3,848 subjects were discharged from hospital with a main diagnosis of MI. Of these, 3,369 (1,036 women, mean age 69.0±11.9 years, and 2,333 men, mean age 60.6±12.6 years) satisfied the inclusion/exclusion criteria. The age distribution for women of 76 (7.3%), 402 (38.8%), and 558 (53.9%) aged <50, 50–69, and 70+ years, respectively, and for men, 465 (19.9%), 1,268 (54.4%), and 600 (25.7%) aged <50, 50–69, and 70+ years, respectively, was significantly different (P<0.001). Prevalence of previous CV hospitalization, diabetes, and CKD was 37.9%, 26.2%, and 7.8%, respectively, while 1,689 (50.1%) patients had been treated with statins and/or antihypertensive drugs and/or antiplatelet drugs in the 12 months before hospital admission. Statins had been prescribed to 570 (16.9%) patients. During hospitalization, 2,409 (71.5%) patients had been treated by statins (Table 1). Treated patients compared to untreated patients were more frequently male, older, and had a higher prevalence of previous CV hospital admissions and a lower prevalence of concomitant diseases. At least a measurement of total cholesterol and LDL cholesterol was present in 3,006 (89.2%) and in 2,558 (75.9%) of patients, respectively. The mean value of both parameters and the percentage of value over the recommended target were significantly higher in treated than in untreated patients (Table 1). At discharge from the hospital, statin treatment had been prescribed to 2,150 (63.8%) patients, and had not been prescribed to 833 (24.7%) patients. In 386 (11.5%) patients, we found no indication regarding statin treatment in the hospital patient case history (Table 2). Younger age, male sex, in-hospital statin treatment, and total and LDL cholesterol levels were significantly different in the three cohorts of patients. The statin prescribed at hospital discharge was generally confirmed by the first prescription made out of hospital, with a percentage ranging from 75% for rosuvastatin up to 87% for simvastatin (Table 3). Among the patients without a prescription of statin at hospital discharge, 412 (49.5%) received a prescription of statin out of the hospital. Among the patients with unknown indications for statins at hospital discharge, 293 (75.9%) patients received a prescription of statin out of the hospital. The statin more frequently prescribed was atorvastatin (1,132 patients), followed by simvastatin (1,127 patients), pravastatin (305 patients), rosuvastatin (130 patients), and other statins (50 patients). A weak difference in mean total cholesterol levels was present among the different types of statins prescribed (atorvastatin was more frequently prescribed for patients with higher values), while no relationship was found between LDL cholesterol levels and types of statins prescribed (Table 4).

Table 1 Participant characteristics by statin treatment during hospitalization

	Statin treatment during hospitalization, n (%)/mean ± SD		P<
	No 960(28.5)	Yes 2,409(71.5)
Age, years	67.3±13.1	61.6±12.6	0.001
Sex, male	600 (62.5)	1,733 (71.9)	0.001
Hospitalization for CV reasons in the previous yeara	352 (36.7)	926 (38.4)	NS
Presence of diabetesa,b	290 (30.2)	594 (24.7)	0.001
Presence of CKDa	110 (11.5)	154 (6.4)	0.001
Total cholesterol,c,d mg/dL	174.8±50.5	194.3±55.4	0.001
LDL-C,c,e mg/dL	107.4±40.6	124.3±45.7	0.001
LDL-C >100 mg/dL	396 (58.1)	1,395 (74.4)	0.001
LDL-C >70 mg/dL	590 (86.6)	1,698 (90.5)	0.01

Notes:

a As inferred from hospital discharge database;

b as inferred from preadmission prescription of specific drugs;

c as inferred from hospital case history;

d as inferred from 3,006 of 3,369 (89.2%) hospital case histories;

e as inferred from 2,558 of 3,369 (75.9%) hospital case histories.

Abbreviations: SD, standard deviation; CV, cardiovascular; NS, not significant; CKD, chronic kidney disease; LDL-C, low-density-lipoprotein cholesterol.

Table 2 Participant characteristics by statin prescription at discharge

	Statin prescription at hospital dischargea, n (%)/mean ± SD			P<
	Yes 2,150 (63.8)	No 833 (24.7)	Unknown 386 (11.5)
Age, years	61.2±12.5	67.3±13.0	65.7±12.6	0.001
Sex, male	1,541 (71.7)	510 (61.2)	282 (73.1)	0.001
Statin treatment during hospitalizationa	2,076 (96.6)	107 (12.8)	226 (58.5)	0.001
Total cholesterol,b mg/dL	193.1±57.5	175.2±50.0	194.1±49.6	0.001
LDL-C,c mg/dL	123.9±45.6	108.5±40.5	117.0±46.7	0.001
LDL-C >100 mg/dL	1,307 (74.1)	361 (59.9)	125 (65.1)	0.001
LDL-C >70 mg/dL	1,596 (90.5)	522 (86.7)	169 (88.0)	0.05

Notes:

a As inferred from hospital case history;

b as inferred from 3,006 of 3,369 (89.2%) hospital case histories;

c as inferred from 2,558 of 3,369 (75.9%) hospital case histories.

Abbreviations: SD, standard deviation; LDL-C, low-density-lipoprotein cholesterol.

Table 3 Relationship between statin prescription at hospital discharge and first statin prescription out of the hospital

Statin prescribed athospital discharge, n %	First statin prescribed at the beginning of follow-up, n %						Total
	Atorvastatin	Pravastatin	Rosuvastatin	Simvastatin	Other statinsa	No statins
Atorvastatin	786	13	20	63	5	52	939
	83.7	1.4	2.1	6.7	0.5	5.5	100
Pravastatin	24	196	5	14	1	15	255
	9.4	76.9	2.0	5.5	0.4	5.9	100
Rosuvastatin	3	1	33	6	0	1	44
	6.8	2.3	75.0	13.6		2.3	100
Simvastatin	39	22	10	786	3	43	903
	4.3	2.4	1.1	87.0	0.3	4.8	100
Other statins	2	0	0	0	7	0	9
	22.2				77.8		100
No statins	155	42	50	141	24	421	833
	18.6	5.0	6.0	16.9	2.9	50.5	100
Unknown	123	31	12	117	10	93	386
	31.9	8.0	3.1	30.3	2.6	24.1	100
Total, n	1,132	305	130	1,127	50	625	3,369

Notes:

a Pooled prescriptions of fluvastatin (32 patients), lovastatin (nine patients), and simvastatin + ezetimibe (nine patients).

Table 4 Relationship between cholesterol levels and first statin prescription out of the hospital

	Statin treatment in follow-up, n (%)/mean ± SD					P<
	Atorvastatin 1,132 (41.3)	Pravastatin 305 (11.1)	Rosuvastatin 130 (4.7)	Simvastatin 1,127 (41.1)	Other statins 50 (1.8)
Total cholesterol,a mg/dL	196.5±54.1	190.6±55.5	191.3±62.3	189.1±58.4	198.4±57.8	0.05
LDL-C,b mg/dL	125.4±45.0	122.8±47.1	120.0±46.6	120.6±46.2	129.6±51.6	NS
LDL-C ≥100 mg/dL	682 (72.5%)	202 (78.3%)	77 (76.2%)	597 (73.1%)	28 (71.8%)	NS
LDL-C ≥70 mg/dL	854 (90.8%)	237 (91.9%)	90 (89.1%)	730 (89.4%)	36 (92.3%)	NS

Notes:

a As inferred from 2,479 of 2,744 (90.3%) hospital case histories;

b as inferred from 2,156 of 2,744 (78.6%) hospital case histories.

Abbreviations: SD, standard deviation; LDL-C, low-density-lipoprotein cholesterol; NS, not significant.

For outpatients, 2,744 (81.4%) patients received at least one prescription of statin, while 625 (18.6%) did not receive prescriptions of statins during the 24-month follow-up period. Younger age, male sex, in-hospital statin treatment, statin prescriptions at hospital discharge, and total and LDL cholesterol levels were significantly more frequent or higher in treated than in untreated patients, while previous hospital admission for CV disease and presence of concomitant diseases were more frequent in untreated than treated patients (Table 5). Among the 2,744 patients treated with statins as outpatients, 115 (4.2%) were defined as occasionals, since they received only one prescription of statin. Occasional patients compared to those persistent were older, more frequently female with concomitant diseases, with a lower percentage of statin treatment during the hospital stay, and lower percentage of statin prescription at discharge from the hospital (Table 6). Among persistent patients, 1,999 (76%) were treated by the same type of statin, 543 (20.7%) by two different type of statins, and 87 (3.3%) by three or more types of statins. Among persistent patients, 1,431 (54.4%) patients showed an MPR ≥80% (Table 7). Percentage of statin treatment during hospitalization and statin prescription at hospital discharge, mean age, and prevalence of male sex were significantly different between the two cohorts of patients. In persistent patients with an adherence to treatment ≥80%, we calculated the daily dose of different types of statins during the 2-year follow-up (Table 8). For atorvastatin, there was an equivalent number of patients treated by a dose ≤20 mg or a dose ranging from 20 mg to 40 mg (44.2% and 47.7%, respectively). For pravastatin, the majority of patients (71.3%) were treated by a dose ranging from 30 mg to 60 mg. For rosuvastatin, there was a weak prevalence of patients treated by a dose ≤10 mg rather than a dose ranging from 10 mg to 20 mg (53.7% and 42.6%, respectively). For simvastatin, there was a weak prevalence of patients treated by a dose ranging from 30 mg to 60 mg rather than a dose ≤30 mg (53.3% and 45.7%, respectively).

Table 5 Participant characteristics by statin treatment at follow-up

	Statin treatment at follow-up, n (%)/mean ± SD		P<
	No 625 (18.6)	Yes 2,744 (81.4)
Age, years	70.7±13.2	61.5±12.8	0.001
Sex, male	352 (56.3)	1,981 (72.2)	0.001
Hospitalization for CV reasons in the previous yeara	261 (41.8)	1,017 (37.1)	0.05
Presence of diabetesa,b	191 (30.6)	693 (25.3)	0.01
Presence of CKDa	84 (13.6)	180 (6.6)	0.001
Statin treatment during hospitalizationc	177 (28.3)	2,232 (81.3)	0.001
Prescription of statins at discharged	111 (20.9)	2,039 (83.2)	0.001
Total cholesterol,e mg/dL	172.2±46.2	192.7±56.5	0.001
LDL-C,f mg/dL	103.8±36.8	122.8±45.7	0.001
LDL-C >100 mg/dL	206 (51.5)	1,588 (73.6)	0.001
LDL-C >70 mg/dL	339 (84.8)	1,949 (90.3)	0.001

Notes:

a As inferred from hospital discharge database;

b as inferred from preadmission prescription of specific drugs;

c as inferred from hospital case history;

d as inferred from 2,983 of 3,369 (88.5%) hospital case histories;

e as inferred from 3,006 of 3,369 (89.2%) hospital case histories;

f as inferred from 2,558 of 3,369 (75.9%) hospital case histories.

Abbreviations: SD, standard deviation; CV, cardiovascular; CKD, chronic kidney disease; LDL-C, low-density-lipoprotein cholesterol.

Table 6 Study participant characteristics by persistence of statin treatment at follow-up

	Statin treatment at follow-up, n (%)/mean ±SD		P<
	Occasional 115 (4.2)	Persistent 2,629 (95.8)
Age, years	67.8±12.4	61.2±12.2	0.001
Sex, male	69 (60.0)	1,912 (72.7)	0.01
Hospitalization for CV reasons in the previous yeara	44 (38.3)	973 (37.0)	NS
Presence of diabetesa,b	43 (37.4)	650 (24.7)	0.001
Presence of CKDa	17 (14.8)	163 (6.2)	0.001
Statin treatment during hospitalizationc	65 (56.5)	2,167 (82.4)	0.001
Prescription of statins at discharged	51 (52.0)	1,988 (84.5)	0.001
Total cholesterol,e mg/dL	185.0±49.7	193.0±56.8	NS
LDL-C,f mg/dL	115.4±40.1	123.1±45.9	NS
LDL-C >100 mg/dL	59 (70.2)	1,527 (73.7)	NS
LDL-C >70 mg/dL	76 (90.5)	1,871 (90.3)	NS

Notes:

a As inferred from hospital discharge database;

b as inferred from preadmission prescription of specific drugs;

c as inferred from hospital case history;

d as inferred from 2,451 of 2,744 (89.3%) hospital case histories;

e as inferred from 2,479 of 2,744 (90.3%) hospital case histories;

f as inferred from 2,156 of 2,744 (78.6%) hospital case histories.

Abbreviations: SD, standard deviation; CV, cardiovascular; NS, not significant; CKD, chronic kidney disease; LDL-C, low-density-lipoprotein cholesterol.

Table 7 Study participant characteristics by level of adherence to statin treatment at follow-up

	Statin treatment at follow-up, n (%)/mean ± SD		P<
	Nonadherent MPR <80% 1,198 (45.6)	Adherent MPR ≥80% 1,431 (54.4)
Age, years	62.8±12.4	59.9±11.8	0.001
Sex, male	848 (70.8)	1,064 (74.4)	0.05
Hospitalization for CV reasons in the previous yeara	467 (39.0)	506 (35.4)	NS
Presence of diabetesa,b	319 (26.6)	331 (23.1)	0.05
Presence of CKDa	79 (6.6)	84 (5.9)	NS
Statin treatment during hospitalizationc	923 (77.0)	1,244 (86.9)	0.001
Prescription of statins at discharged	832 (79.1)	1,156 (88.9)	0.001
Total cholesterol,e mg/dL	155.0±52.4	191.4±60.3	NS
LDL-C,f mg/dL	123.7±43.8	122.5±47.6	NS
LDL-C >100 mg/dL	224 (24.6)	321 (27.7)	NS
LDL-C >70 mg/dL	84 (9.2)	117 (10.1)	NS

Notes:

a As inferred from hospital discharge database;

b as inferred from preadmission prescription of specific drugs;

c as inferred from hospital case history;

d as inferred from 2,353 of 2,629 (89.5%) hospital case histories;

e as inferred from 2,371 of 2,629 (90.2%) hospital case histories;

f as inferred from 2,072 of 2,629 (78.8%) hospital case histories.

Abbreviations: MPR, medication-possession ratio; SD, standard deviation; CV, cardiovascular; NS, not significant; CKD, chronic kidney disease; LDL-C, low-density-lipoprotein cholesterol.

Table 8 Daily dose of different types of statins prescribed during follow-up to those persistent with adherence to treatment ≥80%

Statin prescribed during follow-up	Daily dose, mg	Patients treated
		n	%
Atorvastatin	≤20	280	44.2
	>20–≤40	302	47.7
	>40	51	8.1
Pravastatin	≤30	34	26.4
	>30–≤60	92	71.3
	>60	3	2.3
Rosuvastatin	≤10	29	53.7
	>10–≤20	23	42.6
	>20	2	3.7
Simvastatin	≤30	275	45.7
	>30–≤60	321	53.3
	>60	6	1.0

Note: Fourteen patients treated with other statins were not considered.

Logistic regression analysis with relative risk and 95% confidence interval was used to predict 2-year nonadherence to statin treatment (Table 9). Neither sex nor CKD had a significant role in determining adherence to statin treatment. A significant decrease in adherence was related to increasing age and presence of previous CV diseases, as well as diabetes. A significant increase in adherence was related to statin treatment before actual MI, statin treatment during hospitalization for actual MI, and contemporary treatment with antihypertensive and antiplatelet drugs during the 2-year follow-up. With regard to the type of statin, atorvastatin, which was selected as the reference as the most frequently prescribed, resulted in the best treatment adherence.

Table 9 Logistic regression analysis to predict 2-year nonadherence to statin treatment

	RR	95% CI		P-value
		Inferior	Superior
Age, years	1.019	1.011	1.026	0.000
Sex	0.949	0.787	1.143	0.580
Previous statin treatment	0.664	0.542	0.814	0.000
Presence of diabetes	1.296	1.046	1.605	0.018
Previous CV hospitalizations	1.301	1.076	1.573	0.007
Presence of CKD	0.907	0.647	1.270	0.569
Statin treatment during hospitalization	0.564	0.454	0.701	0.000
Antihypertensive/antiplatelet treatment	0.380	0.243	0.593	0.000
Statin
Atorvastatin (reference)
Pravastatin	1.642	1.253	2.151	0.000
Rosuvastatin	1.576	1.055	2.355	0.026
Simvastatin	1.229	1.031	1.466	0.022
Other statins	2.429	1.233	4.785	0.010

Abbreviations: CI, confidence interval; RR, relative risk; CV, cardiovascular; CKD, chronic kidney disease.

Discussion

In this study of in-hospital and 2-year adherence to the use of statin for secondary prevention following an MI, we found that patient use of evidence-based therapy remains suboptimal. More concerning, 28.5% of patients had not been consistently treated with statins during their hospital stay for MI, and 36.2% of patients did not received a statin prescription at hospital discharge. Moreover, for outpatients, 57.6% of patients were not treated, occasional users, or underusers (MPR lower than 80%). A number of measured factors were associated either positively or negatively with consistent acute and long-term use of this efficacy-proved therapy. In the present study, statins were less frequently prescribed to women than men, as previously described.¹⁸ Paradoxically, in our analysis, as observed in other settings,^19,20 either during the hospitalization or during the follow-up, the use of statins was lower among elderly patients and patients with diabetes and CKD, who have the highest risk of poor CV outcomes and who could potentially benefit the most from sustained therapy. These findings suggest the need to design educational programs targeted at patients at high risk of underuse of medications in secondary CV prevention. Unfortunately, preliminary reports suggest that the adoption of quality-improvement programs have modest effects on improving adherence to the use of life-saving therapies.^21,22 We found that total and LDL cholesterol levels were significantly lower in statin-untreated patients either during the hospitalization or during the follow-up, even if nearly 90% of our patients had a value of LDL cholesterol >70 mg/dL. These findings are in contrast with current therapeutic guidelines^6,8 that tends to emphasizes the need to reach a particular LDL cholesterol target, ie, <100 mg/dL or <70 mg/dL in very high-risk patients. Conversely, in the present study, lipid levels were not associated with adherence to treatment in follow-up. In addition, the absence of any relationship between lipid levels and the choice of statin to prescribe provides evidence that physicians treat statins as a class and do not choose their statins based on clinical trial evidence, as previously observed.²³ Importantly, we also observed that among the strongest factors associated with consistent use of statins, there was baseline use of other evidence-based medications in the form of antihypertensive and antiplatelet drugs. From previous studies, it is clear that an important factor in long-term use of statins is prescription at the time of discharge after an acute event.^24,25 In a single-center study of 600 patients,¹³ 23% of patients with CAD documented by coronary angiography and prescribed a statin at discharge were not using a statin at an average of 3 years of follow-up. Our results were similar: during the 2-year follow-up, the majority of occasional patients or nonadherent patients had not received a statin prescription at hospital discharge. In our study, 606 (16.9%) patients were on statins before the hospital admission for MI. This is in accordance with findings of other studies,^26,27 where only 15%–30% of patients admitted for MI were taking statins before their event, but with 37.9% of patients with a previous hospitalization for CV reasons, this emphasizes the lack of efficacious primary and secondary prevention of CV disease.

Our study has a number of strengths. First, it included all patients with an MI admitted to hospitals located in nine Italian regions, and unlike clinical trials, involved a representative sample of unselected subjects (both men and women) and reflected a real-world setting. Second, we had information not only on statin treatment posthospitalization but also information regarding the period before and during hospitalization containing variables not typically available in prescription claim databases. Therefore, we were able to describe in each patient the links between different setting and clinical condition.

Our study has several limitations. First, information on the severity of MI was not available to us. Second, we restricted our analysis to recent years (2003–2007) to reflect the therapeutic policy after the publication of the stringent guidelines for lipid lowering in patients with CAD.^6,7 Third, the reasons for discontinuation of statins are not available in the claim databases. Also, we used issued prescriptions (information derived from electronic records) to estimate actual pill intake. However, this is a standard method used in population-based databases.²⁸ Fourth, as is true of most observational studies, we may not have been able to completely control for potential confounders related to severity of illness or excess comorbidities. Therefore, although we adjusted for a number of important risk factors and potential confounders, our study may have been affected by residual confounding. Finally, a further weakness is our lack of follow-up on total and LDL cholesterol measurement. We believe that it may be considered unimportant. In the 1,431 patients with a MPR ≥80%, we determined the dose of statin according to defined daily dose. A standard statin regimen (ie, 20–40 mg simvastatin daily) is expected to reduce LDL cholesterol by about a third, while more potent statins (ie, 40–80 mg atorvastatin daily or 10–20 mg rosuvastatin daily) can halve LDL cholesterol.²⁹ We believe that adherence to treatment and determination of daily dose could be considered good indicators of efficacy in population-based studies.

Conclusion

Patients after an MI are at high risk of CV events (including death), and should be treated aggressively in the absence of clear contraindications. Since the statin-undertreatment rate in routine care is still high, physicians need to increase the awareness of patients regarding the implications of underuse of their medications (sometimes despite doctors’ recommendations). It is important to emphasize that discontinuation of statin therapy following an acute MI is associated with higher total mortality,³⁰ so physicians have to encourage higher adherence to effective cardioprotective therapy. Although continued improvement in short-term use and prescription of these agents is needed, considerable attention must also be focused on understanding and improving long-term adherence to achieve the full potential of these treatments to improve clinical outcomes.

Disclosure

This work was supported by an unconditional grant of Pfizer Italy. The authors report no other conflicts of interest in this work.